News
Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown
Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; Novo’s has fallen by as much (see chart 2). Lilly’s edge rests on a more effective drug, better execution, some keener pricing and a stronger pipeline.
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Despite last ...
The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...
A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...
Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes ...
Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...
Novo Nordisk A/S surged on expectations that some competition for its blockbuster obesity shot Wegovy will subside, paving ...
Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...
Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...
But Eli Lilly CEO David Ricks waved off the deal Thursday, telling Yahoo Finance in an interview that the company is focused ...
Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback